Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Taylor Pedersen

Family Medicine Casper, WY Doctor of Osteopathy

NPI 1043740202 CMS profile 8790075

1522 E A St, Casper, WY 82601

Open in the dashboard

General payments

$3,934

232 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Taylor Pedersen of Casper, WY is reported in the CMS Open Payments database as having received $3,934 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $585 29
2024 General $639 46
2023 General $1,092 40
2022 General $588 39
2021 General $734 57
2020 General $297 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Taylor Pedersen
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Taylor Pedersen were reported at $585. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Taylor Pedersen Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $297 $120 $32–$415 $114
2021 $734 $137 $35–$551 $132
2022 $588 $137 $37–$512 $149
2023 $1,092 $149 $42–$545 $160
2024 $639 $156 $44–$560 $164
2025 $585 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $583 34 payments
  2. Henry Schein, Inc. $485 2 payments
  3. Lilly USA, LLC $371 23 payments
  4. Pfizer Inc. $352 33 payments
  5. AbbVie, Inc. $294 25 payments
  6. Merck Sharp & Dohme Corporation $260 16 payments
  7. Novo Nordisk Inc $241 13 payments
  8. GlaxoSmithKline, LLC. $147 11 payments
  9. Amgen Inc. $133 10 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $132 9 payments
  11. Other $938 56 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,449 230 payments
  2. Travel and Lodging $485 2 payments
Products named General payments · program years 2020–2025
  1. MOUNJARO $265 16 payments
  2. FARXIGA $243 13 payments
  3. NURTEC ODT $217 26 payments
  4. BREZTRI $216 12 payments
  5. Ozempic $203 11 payments
  6. ZAVZPRET $175 22 payments
  7. RYBELSUS $168 9 payments
  8. AIRSUPRA $142 7 payments
  9. COMIRNATY $138 9 payments
  10. Repatha $133 10 payments
  11. Other $3,343 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record